Evidence map›Paper›PMID 32404163›Full record

ArticleBMC medical informatics and decision making2020

Coronary heart disease and mortality following a breast cancer diagnosis.

Aixia Guo, Kathleen W Zhang, Kristi Reynolds, Randi E Foraker

Open access · goldAbstract read
In one paragraph

Article in BMC medical informatics and decision making, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. A Systematic Review of Cardiovascular Health Among Cancer Survivors.International journal of environmental research and public health · 2025
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Aixia GuoInstitute for Informatics (I2), Washington University School of Medicine, 600 S. Taylor Avenue, Suite 102, Campus Box 8102, St. Louis, MO, 63110, USA.
Kathleen W ZhangCardiovascular Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Kristi ReynoldsDepartment of Research and Evaluation Southern California Permanente Medical Group, Pasadena, California, USA.
Randi E ForakerInstitute for Informatics (I2), Washington University School of Medicine, 600 S. Taylor Avenue, Suite 102, Campus Box 8102, St. Louis, MO, 63110, USA. randi.foraker@wustl.edu.ORCID 0000-0001-9255-9394
Washington University in St. Louis · USKaiser Permanente · US

Funding

Washington University Implementation Science Center for Cancer Control (WU-ISCCC)P50CA244431 · NCI · WASHINGTON UNIVERSITY · PI JAMES, AIMEE S · 2019 to 2023
$8.0M
NCI NIH HHS P50 CA244431
6 · The paper itself

Abstract

backgroundCoronary heart disease (CHD) is a leading cause of morbidity and mortality for breast cancer survivors, yet the joint effect of adverse cardiovascular health (CVH) and cardiotoxic cancer treatments on post-treatment CHD and death has not been quantified.

methodsWe conducted statistical and machine learning approaches to evaluate 10-year risk of these outcomes among 1934 women diagnosed with breast cancer during 2006 and 2007. Overall CVH scores were classified as poor, intermediate, or ideal for 5 factors, smoking, body mass index, blood pressure, glucose/hemoglobin A1c, and cholesterol from clinical data within 5 years prior to the breast cancer diagnosis. The receipt of potentially cardiotoxic breast cancer treatments was indicated if the patient received anthracyclines or hormone therapies. We modeled the outcomes of post-cancer diagnosis CHD and death, respectively.

resultsResults of these approaches indicated that the joint effect of poor CVH and receipt of cardiotoxic treatments on CHD (75.9%) and death (39.5%) was significantly higher than their independent effects [poor CVH (55.9%) and cardiotoxic treatments (43.6%) for CHD, and poor CVH (29.4%) and cardiotoxic treatments (35.8%) for death].

conclusionsBetter CVH appears to be protective against the development of CHD even among women who had received potentially cardiotoxic treatments. This study determined the extent to which attainment of ideal CVH is important not only for CHD and mortality outcomes among women diagnosed with breast cancer.

Indexed as

Breast NeoplasmsCoronary DiseaseAdultAgedAged, 80 and overBlood PressureBody Mass IndexFemaleHealth StatusHumansMiddle AgedRisk FactorsYoung AdultBreast CancerCancer informaticsCancer treatmentsCoronary heart diseaseDeathInteractionsMachine learningPrecision medicine

Identifiers

PMID32404163
PMCPMC7218836
OpenAlexW3028280540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.